CCP-020

At a Glance

• Epidermolysis bullosa simplex (EBS) is the most common form of EB, and causes painful blisters in the epidermis, or outer layer of skin
• EBS ranges from mild, yet fragile blistering, mainly on hands and feet, to a more general distribution of blistering on the skin
• Supportive care may include wound care, use of non-adhesive bandages as well as pain management
• EBS can be severely debilitating, and currently has no cure

Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and Ms. Martin. Used with permission.
Meet Lindsay

Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and Mr. Feather. Used with permission.
Meet Mark

About Epidermolysis Bullosa Simplex

Epidermolysis bullosa simplex (EBS) is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies. The disease can be severely debilitating and there are no treatment options currently available.

About CCP-020

CCP-020 (diacerein topical ointment) is a new drug in development for the treatment of EBS and other forms of EB. It is believed to block an important inflammatory signaling pathway.

The U. S. Food and Drug Administration has granted Orphan Drug designation, Rare Pediatric Disease designation, and Fast Track designation to CCP-020 for treatment of EBS.

Explore Advocacy & Educational Resources